Discontinuing cotrimoxazole preventive therapy in HIV-infected adults who are stable on antiretroviral treatment in Uganda (COSTOP): A randomised placebo controlled trial.
Zacchaeus AnywaineJonathan LevinRonnie KasiryeJoseph Kayiira LutaakomeAndrew AbaasaAndrew NunnHeiner GrosskurthPaula Munderinull nullPublished in: PloS one (2018)
In ART stable patients with CD4 counts ≥250 cells/μL, continued CPT significantly reduces risk of severe bacterial infections and protects against malaria, while discontinuing CPT reduces haematological adverse events.
Keyphrases
- hiv infected
- antiretroviral therapy
- double blind
- human immunodeficiency virus
- induced apoptosis
- clinical trial
- study protocol
- cell cycle arrest
- hiv positive
- hiv aids
- hiv infected patients
- open label
- placebo controlled
- cell death
- oxidative stress
- mesenchymal stem cells
- cell proliferation
- hepatitis c virus
- cell therapy
- pi k akt